ImmunoPrecise Antibodies News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.12.24	ImmunoPrecise Antibodies: Q2 Earnings Insights (Benzinga)
09.12.24	Ausblick: ImmunoPrecise Antibodies verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
15.09.24	Ausblick: ImmunoPrecise Antibodies zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
28.07.24	Ausblick: ImmunoPrecise Antibodies präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
28.03.24	EXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare Applications (Benzinga)
13.03.24	Earnings Outlook For ImmunoPrecise Antibodies (Benzinga)
06.12.23	Pre-market Movers: DUNE, IPA, S, PHIO, ACRS… (RTTNews)
30.05.23	IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology (Businesswire)
17.05.23	IPA to Present at Jefferies Healthcare Conference 2023 (Businesswire)
27.03.23	European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology (Businesswire)
11.11.22	Pre-market Movers: SNAL, VS, OLMA, MTTR, HLTH… (RTTNews)
09.05.22	IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant (Businesswire)
14.04.22	IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings (Businesswire)
17.03.22	AKU's Q4 Revenue Up 168%, CPRX Expects 2022 Revenue To Grow 38%-45%, VIRX Awaits NAVAL-1 Trial Data (RTTNews)
16.03.22	ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022 (Businesswire)
14.03.22	IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense (Businesswire)
09.03.22	IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03 (Businesswire)
08.03.22	ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET (Businesswire)
31.01.22	Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission (Businesswire)
18.01.22	ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability (Businesswire)
17.01.22	ImmunoPrecise Antibodies Announces Grant of Stock Options (Businesswire)
11.01.22	ImmunoPrecise Antibodies Announces Grant of Stock Options (Businesswire)
03.01.22	ImmunoPrecise Antibodies Announces Grant of Stock Options (Businesswire)
20.12.21	ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration (Businesswire)
22.06.21	Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform (PR Newswire)
22.06.21	Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform (Businesswire)
22.06.21	Eurofins Discovery et ImmunoPrecise annoncent leur collaboration pour étendre leur plateforme de découverte d'anticorps (PR Newswire)
22.06.21	Eurofins Discovery und ImmunoPrecise kündigen Zusammenarbeit zur Erweiterung ihrer Antikörper-Forschungsplattform (PR Newswire)
22.06.21	Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform (PR Newswire)
17.06.21	Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction (Businesswire)
15.06.21	Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event (Businesswire)
03.06.21	ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche (Businesswire)
25.05.21	ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board (Businesswire)
20.05.21	ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing (Businesswire)
08.04.21	ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease (Businesswire)
25.03.21	ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern (Businesswire)
17.03.21	ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year (Businesswire)
16.03.21	ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies (Businesswire)
04.03.21	ImmunoPrecise Announces Participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021 (Virtual Conference) (Businesswire)
19.02.21	ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™ Monoclonal Antibody Cocktail Candidate Against COVID-19 (Businesswire)
11.02.21	IPA Announces Closing of Over-Allotment Option Associated with the Recently Completed Bought Deal Offering of Common Shares (Businesswire)
08.02.21	IPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares (Businesswire)
04.02.21	IPA Increases Previously Announced Bought Deal Offering of Common Shares to $21.7 Million (Businesswire)
03.02.21	IPA Announces $10.0 Million Bought Deal Offering of Common Shares (Businesswire)
06.01.21	MRKR Soars As FDA Lifts Hold On MT-401, RYTM Sells Priority Review Voucher, MLND Dumps MLE-301 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	76.62	0.39 %	K V
Part Grp Hldg	1’271.50	0.36 %	K V
Holcim	89.08	0.25 %	K V
Logitech Intl	74.82	-0.05 %	K V
Lonza Grp	540.60	-0.15 %	K V
UBS Group	27.82	-1.24 %	K V
Sika	223.10	-1.37 %	K V
Nestle	74.10	-1.49 %	K V
Swiss Re	129.60	-1.78 %	K V
Givaudan	3’961.00	-2.46 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ImmunoPrecise Antibodies Ltd Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten